Heart Failure Is Getting Worse. Understanding Why Is the First Step.

Heart failure is one of the most common serious medical conditions in the world, and by most measures it is getting worse rather than better.

The scale is difficult to overstate. More than 64 million people worldwide are currently living with heart failure, according to a comprehensive review published in Cardiovascular Research. In the United States alone, the Heart Failure Society of America’s HF Stats 2025 report puts the number at approximately 6.7 million Americans over the age of 20 – a figure projected to reach 8.7 million by 2030, 10.3 million by 2040 and 11.4 million by 2050.

In Canada, an estimated three-quarters of a million people live with the condition, and more than 90,000 Canadians over the age of 40 are newly diagnosed every year.

The lifetime risk of developing heart failure has reached one in four. In 2022, heart failure was a contributing cause in 425,147 deaths in the United States, accounting for 45% of all cardiovascular deaths. Total costs associated with managing the condition in the US are projected to approach $858 billion by 2050.

Mortality rates have been rising since 2012, with a pronounced acceleration in 2020 and 2021. Age-adjusted death rates in 2021 were higher than they were in 1999, despite the volume of research investment and therapeutic development that has occurred over that period.

The numbers make it clear: the gap between the tools the field has, and the scale of need is widening. Part of the explanation lies in how the disease itself has changed.

Heart failure is not a single condition. It is an umbrella term for several distinct syndromes that share some symptoms but differ substantially in their mechanisms and how they respond to treatment. The form growing fastest (and proving hardest to address) is heart failure with preserved ejection fraction, or HFpEF. It now accounts for roughly half of all heart failure cases globally, and its share continues to rise as populations age and rates of obesity, diabetes, and high blood pressure increase.

HFpEF is not simply a variant of familiar heart failure. Its causes, patient profile and underlying biology are distinct enough that the therapies developed over decades for other forms of the disease have, in large part, failed to work here. Understanding that distinction (and what it means for how the disease needs to be approached) is where the most consequential conversation in cardiovascular medicine is currently happening.

The HF Stats 2025 data also highlights a delivery problem that compounds the treatment gap. Fewer than one in four eligible patients with the form of heart failure where therapies are best established are receiving the full recommended treatment. For patients living with HFpEF, where the options are fewer and the clinical guidance less definitive, the gap is wider still.

What the data makes clear is that the field cannot solve this problem by refining the approaches that have already underperformed. HFpEF in particular demands a different way of thinking about disease – one that starts upstream, with the biological processes driving progression, rather than downstream with the structural damage those processes eventually produce.

That shift is where the most consequential work in cardiovascular medicine is now happening, and it is the scientific premise at the center of Cardiol Therapeutics’ research programs in inflammatory cardiac disease.